221 related articles for article (PubMed ID: 25377474)
1. PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.
Cortez V; Samayoa C; Zamora A; Martinez L; Tekmal RR; Vadlamudi RK
Cancer Res; 2014 Dec; 74(24):7395-405. PubMed ID: 25377474
[TBL] [Abstract][Full Text] [Related]
2. Regulation of aromatase induction by nuclear receptor coregulator PELP1.
Vadlamudi RK; Rajhans R; Chakravarty D; Nair BC; Nair SS; Evans DB; Chen S; Tekmal RR
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):211-8. PubMed ID: 19800002
[TBL] [Abstract][Full Text] [Related]
3. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.
Nair BC; Nair SS; Chakravarty D; Challa R; Manavathi B; Yew PR; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2010 Sep; 70(18):7166-75. PubMed ID: 20807815
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Cortez V; Mann M; Tekmal S; Suzuki T; Miyata N; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Vadlamudi RK
Breast Cancer Res; 2012 Jul; 14(4):R108. PubMed ID: 22812534
[TBL] [Abstract][Full Text] [Related]
6. Interaction of transcription factor AP-2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling.
Liu J; Liu Z; Li M; Tang W; Pratap UP; Luo Y; Altwegg KA; Li X; Zou Y; Zhu H; Sareddy GR; Viswanadhapalli S; Vadlamudi RK
Mol Oncol; 2021 Apr; 15(4):1146-1161. PubMed ID: 33269540
[TBL] [Abstract][Full Text] [Related]
7. Significance of PELP1 in ER-negative breast cancer metastasis.
Roy S; Chakravarty D; Cortez V; De Mukhopadhyay K; Bandyopadhyay A; Ahn JM; Raj GV; Tekmal RR; Sun L; Vadlamudi RK
Mol Cancer Res; 2012 Jan; 10(1):25-33. PubMed ID: 22086908
[TBL] [Abstract][Full Text] [Related]
8. Significance of ER-Src axis in hormonal therapy resistance.
Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
[TBL] [Abstract][Full Text] [Related]
9. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
[TBL] [Abstract][Full Text] [Related]
10. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Rajhans R; Nair HB; Nair SS; Cortez V; Ikuko K; Kirma NB; Zhou D; Holden AE; Brann DW; Chen S; Tekmal RR; Vadlamudi RK
Mol Endocrinol; 2008 Mar; 22(3):649-64. PubMed ID: 18079323
[TBL] [Abstract][Full Text] [Related]
11. Cancer Stem Cell Phenotypes in ER
Truong TH; Hu H; Temiz NA; Hagen KM; Girard BJ; Brady NJ; Schwertfeger KL; Lange CA; Ostrander JH
Mol Cancer Res; 2018 Apr; 16(4):707-719. PubMed ID: 29348189
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
[TBL] [Abstract][Full Text] [Related]
13. Loss of cyclin D1 in concert with deregulated estrogen receptor alpha expression induces DNA damage response activation and interrupts mammary gland morphogenesis.
Frech MS; Torre KM; Robinson GW; Furth PA
Oncogene; 2008 May; 27(22):3186-93. PubMed ID: 18071314
[TBL] [Abstract][Full Text] [Related]
14. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.
Roy SS; Gonugunta VK; Bandyopadhyay A; Rao MK; Goodall GJ; Sun LZ; Tekmal RR; Vadlamudi RK
Oncogene; 2014 Jul; 33(28):3707-16. PubMed ID: 23975430
[TBL] [Abstract][Full Text] [Related]
15. PELP1 oncogenic functions involve alternative splicing via PRMT6.
Mann M; Zou Y; Chen Y; Brann D; Vadlamudi R
Mol Oncol; 2014 Mar; 8(2):389-400. PubMed ID: 24447537
[TBL] [Abstract][Full Text] [Related]
16. PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER
Truong TH; Benner EA; Hagen KM; Temiz NA; Kerkvliet CP; Wang Y; Cortes-Sanchez E; Yang CH; Trousdell MC; Pengo T; Guillen KP; Welm BE; Dos Santos CO; Telang S; Lange CA; Ostrander JH
Oncogene; 2021 Jun; 40(25):4384-4397. PubMed ID: 34103681
[TBL] [Abstract][Full Text] [Related]
17. PELP1: Structure, biological function and clinical significance.
Sareddy GR; Vadlamudi RK
Gene; 2016 Jul; 585(1):128-134. PubMed ID: 26997260
[TBL] [Abstract][Full Text] [Related]
18. Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice.
Tian J; Berton TR; Shirley SH; Lambertz I; Gimenez-Conti IB; DiGiovanni J; Korach KS; Conti CJ; Fuchs-Young R
J Clin Invest; 2012 Jan; 122(1):192-204. PubMed ID: 22182837
[TBL] [Abstract][Full Text] [Related]
19. Altered Expression of
Englert-Golon M; Andrusiewicz M; Żbikowska A; Chmielewska M; Sajdak S; Kotwicka M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207568
[TBL] [Abstract][Full Text] [Related]
20. Extranuclear coactivator signaling confers insensitivity to tamoxifen.
Kumar R; Zhang H; Holm C; Vadlamudi RK; Landberg G; Rayala SK
Clin Cancer Res; 2009 Jun; 15(12):4123-30. PubMed ID: 19470742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
